Black Diamond ended the third quarter of 2024 with approximately $112.7 million in cash, cash equivalents and investments which the Company believes is sufficient to fund its anticipated operating expenses and capital expenditure requirements into the second quarter of 2026
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDTX:
- BDTX Earnings this Week: How Will it Perform?
- 3 Best Stocks to Buy Now, 10/8/2024, According to Top Analysts
- Black Diamond Therapeutics Restructures to Focus on Oncology Lead Program
- Black Diamond CFO Fang Ni, CPO Elizabeth Montgomery to depart in restructuring
- Black Diamond Therapeutics price target raised to $18 from $15 at Stifel